philip_hammond

Hammond suggests NHS may receive cash boost

pharmafile | March 14, 2018 | News story | Medical Communications, Research and Development Autumn Budget, NHS, UK, biotech, drugs, pharma, pharmaceutical 

The pressures on the NHS over the winter months exposed serious cracks in the service, with issues regarding underfunding, struggles to recruit enough staff and overcrowded hospitals all being widely reported.

The Chancellor of Exchequer, Philip Hammond, eventually released additional funds to the service in his Autumn budget, with an additional £2.8 billion provided to the service over the next two years, but there is still huge pressure on the service and calls for more cash are expected.

Pre-empting these calls, in an interview with the BBC, shortly after the Spring Statement was released, Hammond suggested that there may be room to free up more cash for the NHS in the next budget.

As part of the Spring Statement, The Office for Budget Responsibility’s (OBR) report on economic growth was cited in its prediction of growth to improve in 2018, up from 1.4% to 1.5%. Alongside this was the announcement that borrowing would fall through to the period 2022, from 2.2% of GDP in 2017 to 0.9%.

Speaking to the BBC, Hammond said: “The evidence is clearly there that our population is getting older, that technology is developing in a way that makes intervention possible and desirable in the health service, and that does represent a continuous upward pressure […] I hope that we will see an improvement in the public finances that were hinted at in today’s OBR report. I would hope that those would be carried through into the autumn report and that will allow us then to use some of that headroom to increase spending on our public services.”

One of the main reasons for the uptick in economic growth is the current strength of the global economy.

However, not everything was rosy in the OBR report, with growth for 2021 and 2022 downgraded. The office was also unable to form a clear picture of the economy post-Brexit due to the lack of clear guidelines on what deal the government is pushing for and expecting.

Ben Hargreaves

Related Content

NICE recommends migraine treatment for NHS use

The National Institute for Health and Care Excellence (NICE) has shared draft guidance recommending AbbVie’s …

Novo Nordisk launches Wegovy in the UK

Novo Nordisk has today announced that Wegovy (semaglutide injection) is now available in the UK …

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Latest content